A synthesis of cost-utility analysis literature in infectious disease

Lancet Infectious Diseases

Volumn 5, Issue 6, 2005, Pages 383-391

  Stone, Patricia W ^a   Schackman, Bruce R ^b   Neukermans, Christopher P ^b   Olchanski, Natalia ^c   Greenberg, Dan ^d   Rosen, Allison B ^e   Neumann, Peter J ^c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c HARVARD CENTER FOR RISK ANALYSIS   (United States)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; BLOOD; CALCULATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIAGNOSTIC PROCEDURE; ECONOMIC ASPECT; GOVERNMENT; HEALTH; HEALTH BEHAVIOR; HEALTH EDUCATION; HUMAN; IMMUNIZATION; INFECTION; INFECTION PREVENTION; MEDICAL DECISION MAKING; MEDICAL LITERATURE; METHODOLOGY; ORGANIZATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; PUBLIC HEALTH SERVICE; QUALITATIVE ANALYSIS; QUALITY OF LIFE; REGISTER; RESOURCE ALLOCATION; REVIEW; SAFETY; SCORING SYSTEM; SENSITIVITY ANALYSIS; SOCIAL ASPECT; STANDARDIZATION; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TIME;

ANTI-BACTERIAL AGENTS; COMMUNICABLE DISEASES; COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION; PERIODICALS; PUBLISHING; QUALITY-ADJUSTED LIFE YEARS; TIME FACTORS;

EID: 20344387844     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(05)70142-0     Document Type: Review

References (50)

1. WHO The World Health Report 2004 WHO Geneva http://www.who.int/whr/2004/ en/index.html (accessed April 25, 2005)
2. DE Zoutman, BD Ford, E Bryce The state of infection surveillance and control in Canadian acute care hospitals Am J Infect Control 31 2003 266 272
3. N Graves, TM Nicholls, AJ Morris Modeling the costs of hospital-acquired infections in New Zealand Infect Control Hosp Epidemiol 24 2003 214 223
4. PW Stone, CR Curran, S Bakken Economic evidence for evidence-based practice J Nurs Scholarsh 34 2002 277 282
5. T Arnesen, L Kapiriri Can the value choices in DALYs influence global priority-setting? Health Policy 70 2004 137 149
6. AA Hyder, G Rotllant, RH Morrow Measuring the burden of disease: healthy life-years Am J Public Health 88 1998 196 202
7. CJ Murray, AK Acharya Understanding DALYs (disability-adjusted life years) J Health Econ 16 1997 703 730
8. K Gerard Cost-utility in practice: a policy maker's guide to the state of the art Health Policy 21 1992 249 279
9. PW Stone, B Liljas, RC Chapman, EA Sandberg, C Bell, PJ Neumann Measuring costs in cost-utility analyses: variations in the literature Int J Technol Assess Health Care 16 2000 111 124
10. E Nord Toward quality assurance in QALY calculations Int J Technol Assess Health Care 9 1993 37 45
11. UE Reinhardt Making economic evaluations respectable Soc Sci Med 45 1997 555 562
12. LB Russell, MR Gold, JE Siegel, N Daniels, MC Weinstein The role of cost-effectiveness analysis in health and medicine JAMA 276 1996 1172 1177
13. MR Gold, JE Siegel, LB Russell, MC Weinstein Cost-effectiveness in health and medicine 1996 Oxford University Press New York
14. JE Siegel, MC Weinstein, LB Russell, MR Gold Recommendations for reporting cost-effectiveness analyses JAMA 276 1996 1339 1341
15. MC Weinstein, JE Siegel, MR Gold, MS Kamlet, LB Russell Recommendations of the Panel on Cost-effectiveness in Health and Medicine JAMA 276 1996 1253 1258
16. RS Taylor, MF Drummond, G Salkeld, SD Sullivan Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle BMJ 329 2004 972 975
17. PJ Neumann, D Greenberg, NV Olchanski, PW Stone, AB Rosen Growth and quality of the cost-utility literature 1976-2001 Value Health 8 2005 3 9
18. PJ Neumann, PW Stone, RH Chapman, EA Sandberg, CM Bell The quality of reporting in published cost-utility analyses, 1976-1997 Ann Intern Med 132 2000 964 972
19. CM Bell, RH Chapman, PW Stone, EA Sandberg, PJ Neumann An off-the-shelf help list: a comprehensive catalog of preference scores from published cost-utility analyses Med Decis Making 21 2001 288 294
20. PE Shrout, JL Fleiss Intraclass correlations: uses in assessing rater reliability Psychol Bull 86 1979 420 428
21. KO McGraw, SP Wong Forming inferences about some intraclass correlation coefficients Psychol Methods 1 1996 30 46
22. S Rhoades The Herfindahl-Hirschman index The Federal Reserve Bulletin 79 1993 188 189
23. RM Rubin, CF Chang A bibliometric analysis of health economics articles in the economics literature: 1991-2000 Health Econ 12 2003 403 414
24. PW Stone, S Teutsch, RH Chapman, C Bell, SJ Goldie, PJ Neumann Cost-utility analyses of clinical preventive services: published ratios, 1976-1997 Am J Prev Med 19 2000 15 23
25. CC Earle, RH Chapman, CS Baker Systematic overview of cost-utility assessments in oncology J Clin Oncol 18 2000 3302 3317
26. B Als-Niesen, W Chen, C Gluud, LL Kjaergard Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 290 2003 921 928
27. J Mauskopf, F Rutten, W Schonfeld Cost-effectiveness league tables: valuable guidance for decision makers? Pharmacoeconomics 21 2003 991 1000
28. M Brisson, WJ Edmunds Economic evaluation of vaccination programs: the impact of herd-immunity Med Decis Making 23 2003 76 82
29. J Coast, RD Smith Antimicrobial resistance: cost and containment Expert Rev Anti Infect Ther 1 2003 241 251
30. RD Smith, J Coast, MR Millar Over-the-counter antimicrobials: the hidden costs of resistance J Antimicrob Chemother 37 1996 1031 1032
31. CM Bell, RH Chapman, PW Stone, EA Sandberg, PJ Neumann An off-the-shelf help list: a comprehensive catalog of preference scores from published cost-utility analyses Med Decis Making 21 2001 288 294
32. ML Messonnier, PS Corso, SM Teutsch, AC Haddix, JR Harris An ounce of prevention... what are the returns? Second edition, 1999 Am J Prev Med 16 1999 248 263
33. Institute of Medicine New vaccines development: establishing priorities, Vol 1. Diseases of importance in the United States 1985 National Academy Press Washington DC
34. Institute of Medicine Vaccines for the 21st century: a tool for decision making 1999 National Academy Press Washington DC
35. MC Weinstein, SJ Goldie, E Losina Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness Ann Intern Med 134 2001 440 450
36. MS Hirsch, F Brun-Vezinet, B Clotet Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel Clin Infect Dis 37 2003 113 128
37. Department of Health and Human Services Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents http://aidsinfo.nih.gov/guidelines (accessed April 20, 2005)
38. SJ Goldie, KM Kuntz, MC Weinstein, KA Freedberg, ML Welton, JM Palefsky The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men JAMA 281 1999 1822 1829
39. SPHS/IDSA, Guidelines for the prevention of opportunistic infections in persons infected with HIV http://www.aidsinfo.nih.gov/guidelines/default_db2. asp?id=69 (accessed April 20, 2005)
40. EP Steinberg, BR Luce Evidence based? Caveat emptor! Health Aff (Millwood) 24 2005 80 92
41. PJ Neumann, N Divi, MT Beinfeld, BS Levine, PS Keenan, EF Halpern, GS Gazelle Medicare's national coverage decisions, 1999-2003: quality of evidence and review times Health Aff (Millwood) 24 2005 243 254
42. F Pang Design, analysis and presentation of multinational economic studies: the need for guidance Pharmacoeconomics 20 2002 75 90
43. D Greenberg, JS Pliskin Preference-based outcome measures in cost-utility analyses. A 20-year overview Int J Technol Assess Health Care 18 2002 461 466
44. K Claxton, M Sculpher, C McCabe Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra Health Econ 14 2005 339 347
45. M Brisson, WJ Edmunds Varicella vaccination in England and Wales: cost-utility analysis Arch Dis Child 88 2003 862 869
46. H Ishida, Y Inoue, JB Wong, K Okita Cost-effectiveness of ribavirin plus interferon alpha-2b for either interferon relapsers or non-responders in chronic hepatitis C: a Japanese trial Hepatol Res 28 2004 125 136
47. SJ Goldie, AD Paltiel, MC Weinstein Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection Am J Med 115 2003 632 641
48. M Brisson, WJ Edmunds Economic evaluation of vaccination programs: the impact of herd-immunity Med Decis Making 23 2003 76 82
49. R Smith New BMJ policy on economic evaluations BMJ 325 2002 1124
50. MF Drummond, TO Jefferson Guidelines for authors and peer reviewers of economic submissions to the BMJ BMJ 313 1996 275 283